Elevated plasma γ-aminobutyrate/glutamate ratio and responses to risperidone antipsychotic treatment in schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 7, 2010, Pages 1273-1278

  Cai, Hua Lin ^a,b   Zhu, Rong Hua ^a   Li, Huan De ^a   Zhang, Xiang Hui ^a   Hu, Li ^a   Yang, Wen ^c   Ye, Hai Sen ^c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c Department of Psychiatry   (China)

Author keywords

aminobutyrate; Glutamate; Plasma; Risperidone; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; ALPRAZOLAM; GLUTAMIC ACID; PALIPERIDONE; RISPERIDONE; TRIHEXYPHENIDYL;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; MALE; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL RATING SCALE; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CHROMATOGRAPHY, LIQUID; FEMALE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUMANS; MALE; RISPERIDONE; SCHIZOPHRENIA; STATISTICS AS TOPIC; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 77956422817     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.07.006     Document Type: Article

References (39)

1. Adinoff B., Kramer G.L., Petty F. Levels of gamma-aminobutyric acid in cerebrospinal fluid and plasma during alcohol withdrawal. Psychiatry Res 1995, 59:137-144.
2. Altamura C.A., Mauri M.C., Ferrara A., Moro A.R., D'Andrea G., Zamberlan F. Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 1993, 150:1731-1733.
3. American Psychiatry Association Diagonostic and Statistical Manual of Mental Disorder 2000, text revision (DSM-IV-TR), American Psychiatric Association, Washington. fourth ed.
4. Arrue A., Davila R., Zumarraga M., Basterreche N., Gonzalez-Torres M.A., Goienetxea B., et al. GABA and homovanillic acid in the plasma of Schizophrenic and bipolar I patients. Neurochem Res 2010, 35:247-253.
5. Benes F. Neural circuitry models of schizophrenia: is it dopamine, GABA, glutamate, or something else?. Biol Psychiatry 2009, 65:1003-1005.
6. Bergink V., van Megen H., Westenberg H. Glutamate and anxiety. Eur Neuropsychopharmacol 2004, 14:175-183.
7. Bjork J.M., Moeller F.G., Kramer G.L., Kram M., Suris A., Rush A.J., et al. Plasma GABA levels correlate with aggressiveness in relatives of patients with unipolar depressive disorder. Psychiatry Res 2001, 101:131-136.
8. Cai H.L., Zhu R.H., Li H.D. Determination of dansylated monoamine and amino acid neurotransmitters and their metabolites in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry. Anal Biochem 2010, 396:103-111.
9. Castillo J., Davalos A., Noya M. Progression of ischaemic stroke and excitotoxic aminoacids. Lancet 1997, 349:79-83.
10. Coyle J. The GABA-glutamate connection in schizophrenia: which is the proximate cause?. Biochem Pharmacol 2004, 68:1507-1514.
11. Coyle J. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006, 26:363-382.
12. Evins A.E., Amico E.T., Shih V., Goff D.C. Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. J Neural Transm 1997, 104:761-766.
13. Gilbody S., Wahlbeck K., Adams C. Randomized controlled trials in schizophrenia: a critical perspective on the literature. Acta Psychiatry Scand 2002, 105:243-251.
14. Goff D., Hennen J., Lyoo I., Tsai G., Wald L., Evins A., et al. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol Psychiatry 2002, 51:493-497.
15. Grimm J., See R. Unique activation of extracellular striato-pallidal neurotransmitters in rats following acute risperidone. Brain Res 1998, 801:182-189.
16. Hawkins R.A., O'Kane R.L., Simpson I.A., Vina J.R. Structure of the blood-brain barrier and its role in the transport of amino acids. J Nutr 2006, 136:218S-226S.
17. Jimenez-Jimenez F.J., Molina J.A., Gomez P., Vargas C., de Bustos F., Benito-Leon J., et al. Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer's disease. J Neural Transm 1998, 105:269-277.
18. Kakee A., Takanaga H., Terasaki T., Naito M., Tsuruo T., Sugiyama Y. Efflux of a suppressive neurotransmitter, GABA, across the blood-brain barrier. J Neurochem 2001, 79:110-118.
19. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
20. Kikumoto O., Okamoto Y., Hayakawa H., Yokota N., Kawai K., Motohashi N., et al. Effects of risperidone on catalepsy and cerebral dopamine, serotonin and GABA metabolism in the rat: Comparison with haloperidol. Jpn J Psychopharmacol 1993, 13:39-42.
21. Lewis D., Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of γ-aminobutyric acid and glutamate alterations. Arch Neurol 2006, 63:1372-1376.
22. Maeshima H., Ohnuma T., Sakai Y., Shibata N., Baba H., Ihara H., et al. Increased plasma glutamate by antipsychotic medication and its relationship to glutaminase 1 and 2 genotypes in schizophrenia-Juntendo University Schizophrenia Projects (JUSP). Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1410-1418.
23. Mallolas J., Hurtado O., Castellanos M., Blanco M., Sobrino T., Serena J., et al. A polymorphism in the EAAT2 promoter is associated with higher glutamate concentrations and higher frequency of progressing stroke. J Exp Med 2006, 203:711-717.
24. Matute C., Melone M., Vallejo-Illarramendi A., Conti F. Increased expression of the astrocytic glutamate transporter GLT-1 in the prefrontal cortex of schizophrenics. Glia 2005, 49:451-455.
25. Murray R., Sham P., VanOs J., Zanelli J., Cannon M., McDonald C. A developmental model for similarities and dissimilarities between schizophrenia and bipolar disorder. Schizophr Res 2004, 71:405-416.
26. Ohnuma T., Suzuki T., Arai H. Hypothesis: minimal changes in neural transmission in schizophrenia: decreased glutamatergic and GABAergic functions in the prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:889-894.
27. Palomino A., González-Pinto A., Aldama A., González-Gómez C., Mosquera F., González-García G., et al. Decreased levels of plasma glutamate in patients with first-episode schizophrenia and bipolar disorder. Schizophr Res 2007, 95:174-178.
28. Palomino A., Vallejo-Illarramendi A., González-Pinto A., Aldama A., González-Gómez C., Mosquera F., et al. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr Res 2006, 86:321-322.
29. Petty F. Plasma concentrations of gamma-aminobutyric acid (GABA) and mood disorders: a blood test for manic depressive disease?. Clin Chem 1994, 40:296-302.
30. Petty F., Fulton M., Kramer G.L., Kram M., Davis L.L., Rush A.J. Evidence for the segregation of a major gene for human plasma GABA levels. Mol Psychiatry 1999, 4:587-589.
31. Petty F., Kramer G., Fulton M., Moeller F., Rush A. Low plasma GABA is a trait-like marker for bipolar illness. Neuropsychopharmacology 1993, 9:125-132.
32. Petty F., Rush A.J., Davis J.M., Calabrese J.R., Kimmel S.E., Kramer G.L., et al. Plasma GABA predicts acute response to divalproex in mania. Biol Psychiatry 1996, 39:278-284.
33. Petty F., Sherman A.D. Plasma GABA levels in psychiatric illness. J Affect Disord 1984, 6:131-138.
34. Roy-Byrne P., Cowley D., Hommer D., Greenblatt D., Kramer G., Petty F. Effect of acute and chronic benzodiazepines on plasma GABA in anxious patients and controls. Psychopharmacology 1992, 109:153-156.
35. Smith Q.R. Transport of glutamate and other amino acid at the blood-brain barrier. J Nutr 2000, 130:1016S-1022S.
36. Tortorella A., Monteleone P., Fabrazzo M., Viggiano A., De Luca L., Maj M. Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine. Neuropsychobiology 2001, 44:167-171.
37. van der Heijden F.M.M.A., Tuinier S., Fekkes D., Sijben A.E.S., Kahn R.S., Verhoeven W.M.A. Atypical antipsychotics and the relevance of glutamate and serotonin. Eur Neuropsychopharmacol 2004, 14:259-265.
38. Waagepetersen H.S., Sonnewald U., Schousboe A. Glutamine, Glutamate and GABA: Metabolic Aspects. Handbook of neurochemistry and molecular neurobiology, Amino acid and peptides in the nervous system 2007, 1-22. Springer-Verlag, Berlin Heidelberg. A. Lajtha (Ed.).
39. Wassef A., Baker J., Kochan L.D. GABA and Schizophrenia: A Review of Basic Science and Clinical Studies. J Clin Psychopharmacol 2003, 23:601-640.